FIRRM/C1orf112 is synthetic lethal with PICH and mediates RAD51 dynamics.

Mitosis Proteins / genetics Adenosine Triphosphatases / metabolism DNA Chromatids / metabolism Rad51 Recombinase / genetics DNA Replication / genetics DNA Damage
C1orf112 CP: Molecular biology FIRRM PICH UFBs cell cycle genetic screen mitosis rad51 replication

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
25 07 2023
Historique:
received: 11 11 2022
revised: 21 04 2023
accepted: 05 06 2023
medline: 31 7 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: ppublish

Résumé

Joint DNA molecules are natural byproducts of DNA replication and repair. Persistent joint molecules give rise to ultrafine DNA bridges (UFBs) in mitosis, compromising sister chromatid separation. The DNA translocase PICH (ERCC6L) has a central role in UFB resolution. A genome-wide loss-of-function screen is performed to identify the genetic context of PICH dependency. In addition to genes involved in DNA condensation, centromere stability, and DNA-damage repair, we identify FIGNL1-interacting regulator of recombination and mitosis (FIRRM), formerly known as C1orf112. We find that FIRRM interacts with and stabilizes the AAA

Identifiants

DOI: 10.1016/j.celrep.2023.112668 PMID: 37347663
pubmed: 37347663
pii: S2211-1247(23)00679-4
doi: 10.1016/j.celrep.2023.112668
pii:
doi:

Substances chimiques

Proteins 0
Adenosine Triphosphatases EC 3.6.1.-
DNA 9007-49-2
Rad51 Recombinase EC 2.7.7.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112668

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Colin Stok (C)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Stavroula Tsaridou (S)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Nathalie van den Tempel (N)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Marieke Everts (M)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Elles Wierenga (E)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Femke J Bakker (FJ)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Yannick Kok (Y)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Inês Teles Alves (IT)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Lucas T Jae (LT)

Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universität München, Feodor-Lynen-Straße 25, 81377 Munich, Germany.

Maximilian W D Raas (MWD)

Oncode Institute, Hubrecht Institute, Royal Academy of Arts and Sciences, Uppsalalaan 8, 3584CT Utrecht, the Netherlands; Theoretical Biology and Bioinformatics, Department of Biology, Faculty of Science, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands.

Pim J Huis In 't Veld (PJ)

Department of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, 44227 Dortmund, Germany.

H Rudolf de Boer (HR)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Arkajyoti Bhattacharya (A)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Eleftheria Karanika (E)

Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK.

Harry Warner (H)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Mengting Chen (M)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Bert van de Kooij (B)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Julien Dessapt (J)

CHU de Québec Research Center-Université Laval (L'Hôtel-Dieu de Québec), Cancer Research Center, Université Laval, Québec, QC GIR 3S3, Canada.

Lars Ter Morsche (L)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Polina Perepelkina (P)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Amelie Fradet-Turcotte (A)

CHU de Québec Research Center-Université Laval (L'Hôtel-Dieu de Québec), Cancer Research Center, Université Laval, Québec, QC GIR 3S3, Canada.

Victor Guryev (V)

European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Eelco C Tromer (EC)

Cell Biochemistry, Groningen Biomolecular Sciences and Biotechnology Institute, Faculty of Science and Engineering, University of Groningen, Nijenborgh 7, 9747 AG Groningen, the Netherlands.

Kok-Lung Chan (KL)

Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK.

Rudolf S N Fehrmann (RSN)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.

Marcel A T M van Vugt (MATM)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands. Electronic address: m.vugt@umcg.nl.

Articles similaires

Exploring structural diversity across the protein universe with The Encyclopedia of Domains.

Andy M Lau, Nicola Bordin, Shaun M Kandathil et al.
1.00
Databases, Protein Protein Domains Protein Folding Proteins Deep Learning

A meiotic driver hijacks an epigenetic reader to disrupt mitosis in noncarrier offspring.

Yu Hua, Jianxiu Zhang, Man-Yun Yang et al.
1.00
Schizosaccharomyces Meiosis Schizosaccharomyces pombe Proteins Mitosis Epigenesis, Genetic

iDNA-ITLM: An interpretable and transferable learning model for identifying DNA methylation.

Xia Yu, Cui Yani, Zhichao Wang et al.
1.00
DNA Methylation Humans DNA Animals Machine Learning

Structural basis for human OGG1 processing 8-oxodGuo within nucleosome core particles.

Mengtian Ren, Fabian Gut, Yilan Fan et al.
1.00
DNA Glycosylases Nucleosomes Humans 8-Hydroxy-2'-Deoxyguanosine DNA Repair

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Division du noyau cellulaire › Mitose › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Acid anhydride hydrolases › Adenosine triphosphatases › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Chromatides › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines des groupes de complémentation de l'anémie de Fanconi › Rad51 Recombinase › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Phénomènes génétiques › Réplication de l'ADN › FIRRM/C1orf112 is synthetic lethal with PICH...
questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › FIRRM/C1orf112 is synthetic lethal with PICH...